Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 3Sturge-Weber Syndrome 2Nausea 2Vomiting 1Parasomnias 1Pain 1Neoplasms 1Marijuana Abuse 1Dysgeusia 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Cancer Pain 1Cachexia 1Breast Neoplasms 1Behavior 1Arthralgia 1Appetitive Behavior 1Anxiety Disorders 1

Interventions

Megestrol Acetate 6Standard of Care 3Exercise 3Physical Therapy Modalities 2Nutrition Assessment 2Infliximab 2Blood Specimen Collection 2testosterone enanthate 1remune 1ostarine 1olanzapine-fluoxetine combination 1irinotecan sucrosofate 1clazakizumab 1bermekimab 1anamorelin 1Sodium Chloride 1Radiotherapy 1Preoperative Exercise 1Powders 1Pentoxifylline 1Olanzapine 1Nandrolone Decanoate 1Mirtazapine 1Melatonin 1Megestrol 1Immunologic Techniques 1Ibuprofen 1High-Energy Shock Waves 1Ghrelin 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cachexia × Cannabidiol × Clear all
NCT04585841 2023-07-24

The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy

University of Copenhagen

Phase 1 Completed
32 enrolled

Appetitive Behavior, Cachexia, Marijuana Abuse, Dysgeusia, Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡